Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemia

Leukemia

Volumn 12, Issue 10, 1998, Pages 1518-1521

  Soignet, S L ^a   Benedetti, F ^a   Fleischauer, A ^a   Parker, B A ^b   Truglia, J A ^b   Ra Crisp, M ^b   Warrell Jr , R P ^a,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

9 cis retinoic acid; Acute promyelocytic leukemia; Differentiation

Indexed keywords

ALITRETINOIN; CORTICOSTEROID;

ACUTE MYELOBLASTIC LEUKEMIA; ADVERSE DRUG REACTION; ARTICLE; BONE PAIN; BRAIN HEMORRHAGE; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 9; CLINICAL ARTICLE; CLINICAL TRIAL; DRY SKIN; DYSPNEA; FATIGUE; FLUSHING; HEADACHE; HUMAN; LEUKEMIA REMISSION; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINOIC ACID SYNDROME; VOMITING;

EID: 0031656210     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401150     Document Type: Article

References (11)

1. de Thé H, Chomienne C, Lanotte M et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor-α gene to a novel transcribed locus. Nature 1990; 347: 558-561.
2. Kakizuka A, Miller WH Jr, Umesono K et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66:663-674.
3. Early E, Moore MAS, Kakizuka A et al. Transgenic expression of PML/RARα impairs myelopoiesis. Proc Natl Acad Sci USA 1996; 93: 7900-7904.
4. Fenaux P, Le Dely MC, Castaigne S et al. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood 1993; 82: 3241-3249.
5. Frankel SR, Eardley A, Miller WH Jr et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: results of the New York study. Ann Intern Med 1994; 120: 278-286.
6. Tallman MS, Andersen JW, Schiffer CA et al. All-trans retinoic acid in acute promyelocytic leukemia. New Engl J Med 1997; 337: 1021-1028.
7. Fenaux P, Chastang C, Sanz M et al. ATRA followed by chemotherapy (CT) vs ATRA plus CT and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia (APL): first interim results of APL 93 trial. Blood 1997; 90 (Suppl.): 122a.
8. Avvisati G, Lo Coco F, Diverio D et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390-1398.
9. Soignet S, Fleischauer A, Polyak T et al. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York Study. Cancer Chemotherapy and Pharmacology 1997; 40 (Suppl.): S25-S29.
10. Muindi JRF, Frankel SR, Huselton C et al. Clinical pharmacology of oral all-trans-retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992; 52: 2138-2142.
11. Muindi JRF, Frankel S, Miller WH Jr et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoic 'resistance' in patients with acute promyelocytic leukemia. Blood 1992; 79: 299-303.